Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Estimating utility values for non-alcoholic steatohepatitis health states: a discrete choice experiment.
J Comp Eff Res. 2024 Feb;13(2):e230033. doi: 10.57264/cer-2023-0033. Epub 2024 Jan 16.
J Comp Eff Res. 2024.
PMID: 38226909
Free PMC article.
Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Post-authorization safety study based on multinational cohorts.
Rebordosa C, Thomsen RW, Tave AK, Madsen M, Beachler DC, Martinez D, Garcia-Esteban R, Plana E, Tormos A, Farsani SF, Perez-Gutthann S, Pladevall-Vila M.
Rebordosa C, et al. Among authors: farsani sf.
Diabetes Obes Metab. 2024 Apr;26(4):1291-1304. doi: 10.1111/dom.15429. Epub 2024 Jan 17.
Diabetes Obes Metab. 2024.
PMID: 38234181
Item in Clipboard
Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design.
Savarese G, Settergren C, Schrage B, Thorvaldsen T, Löfman I, Sartipy U, Mellbin L, Meyers A, Farsani SF, Brueckmann M, Brodovicz KG, Vedin O, Asselbergs FW, Dahlström U, Cosentino F, Lund LH.
Savarese G, et al. Among authors: farsani sf.
Int J Cardiol. 2020 Aug 15;313:76-82. doi: 10.1016/j.ijcard.2020.04.068. Epub 2020 Apr 30.
Int J Cardiol. 2020.
PMID: 32360702
Free article.
Item in Clipboard
Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, Kim SC, Najafzadeh M, Koeneman L, Farsani SF, Déruaz-Luyet A, Paik JM, Patorno E.
Htoo PT, et al. Among authors: farsani sf.
JAMA Netw Open. 2022 Oct 3;5(10):e2237606. doi: 10.1001/jamanetworkopen.2022.37606.
JAMA Netw Open. 2022.
PMID: 36264574
Free PMC article.
Item in Clipboard
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Vistisen D, Carstensen B, Elisabetta P, Lanzinger S, Tan EC, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Núñez J, Ha KH, Halvorsen S, Langslet G, Karasik A, Nyström T, Niskanen L, Guleria S, Klement R, Carrasco M, Foersch J, Shay C, Koeneman L, Hoti F, Farsani SF, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K; EMPRISE EU; East Asia Study Group.
Vistisen D, et al. Among authors: farsani sf.
Cardiovasc Diabetol. 2023 Aug 31;22(1):233. doi: 10.1186/s12933-023-01963-9.
Cardiovasc Diabetol. 2023.
PMID: 37653496
Free PMC article.
Item in Clipboard
In Silico Drug-designing Studies on Sulforaphane Analogues: Pharmacophore Mapping, Molecular Docking and QSAR Modeling.
Vaghefinezhad N, Farsani SF, Gharaghani S.
Vaghefinezhad N, et al. Among authors: farsani sf.
Curr Drug Discov Technol. 2021;18(1):139-157. doi: 10.2174/1570163816666191112122047.
Curr Drug Discov Technol. 2021.
PMID: 31721705
Item in Clipboard
Cite
Cite